Clinical Trials · NCT01011556

A Study for the Transdermal Application of Teriparatide

CompletedPhase 2Teriparatide (Approved)
Phase
Phase 2
Recruitment status
Completed
Sponsor
Eli Lilly and Company
Enrollment
233
Start date
Nov 2009
Locations
18 sites, 5 countries
Primary endpoint
Percent Change From Baseline in Lumbar Spine Bone Mineral Density (BMD) at 12 Months
View Teriparatide compound reference